Evidence map›Paper›PMID 29603872›Full record

Trial reportDiabetes, obesity & metabolism2018

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.

Chantal Mathieu, Stefano Del Prato, Fady T Botros, Vivian T Thieu, Imre Pavo, Nan Jia, Axel Haupt, Chrisanthi A Karanikas, Luis-Emilio García-Pérez

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Chantal MathieuClinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium.ORCID 0000-0002-4055-5233
Stefano Del PratoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.ORCID 0000-0002-5388-0270
Fady T BotrosLilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana.
Vivian T ThieuLilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana.
Imre PavoEli Lilly Regional Operations, Vienna, Austria.
Nan JiaLilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana.
Axel HauptLilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana.ORCID 0000-0003-4502-0470
Chrisanthi A KaranikasLilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana.
Luis-Emilio García-PérezLilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana.ORCID 0000-0003-3840-787X
Eli Lilly (United States) · USKU Leuven · BEUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose-dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta-cell function (as measured by HOMA2-%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide-treated patients from AWARD-1, AWARD-3 and AWARD-6 clinical studies were categorised based on their homeostatic model assessment of beta-cell function (HOMA2-%B) tertiles. Changes in glycaemic measures in response to treatment with once-weekly dulaglutide were evaluated in each HOMA2-%B tertile. Patients with low HOMA2-%B had higher baseline glycated haemoglobin (HbA1c), fasting and postprandial blood glucose, and longer duration of diabetes (P < .001, all) (mean low, middle and high tertiles with dulaglutide 1.5 mg: HOMAB-2%B, 31%, 58%, 109%; HbA1c, 8.7%, 7.7%, 7.3%, respectively). At 26 weeks, the low tertile experienced larger reductions in HbA1c compared to the high tertile with dulaglutide 1.5 mg (mean; -1.55% vs. -0.98% [-16.94 vs. -10.71 mmol/mol]). Differences between low and high tertiles disappeared when adjusted for baseline HbA1c (LSM; -1.00 vs. -1.18% [-10.93 vs. -12.90 mmol/mol]). Greater decreases in fasting blood glucose and greater increases in fasting C-peptide were observed in the low tertile. Similar increases in HOMA2-%B were observed in all tertiles. Dulaglutide demonstrated clinically relevant HbA1c reduction irrespective of estimated baseline beta-cell function.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsInsulin ResistanceAgedBiomarkersCohort StudiesC-PeptideDiabetes Mellitus, Type 2Disease ProgressionDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleGlucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesGlycated HemoglobinHumansBiomarkersC-PeptidedulaglutideGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion Proteinsbeta-cell functiondulaglutideGLP-1 receptor agonisttype 2 diabetes

Identifiers

PMID29603872
PMCPMC6055818
OpenAlexW2795350597

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.